parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.13 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in microglia (8 nCPM)	1.00
chemistry Open Targets	compounds already reach it: etanercept, placulumab, infliximab +11	0.90
trials ClinicalTrials.gov	43 Parkinson's trials, 4 stopped	0.93
literature PubMed	1,690 Parkinson's papers of 262,509: well-trodden	0.02
pathways Reactome	11 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 2267

receipt 2274: TNF in dopamine neurons, braak

power: full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.29 (p 0.235, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.148, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TNF in dopamine neurons.

case closed: nothing better to follow up.

receipt 2273: TNF in microglia, braak

power: full sample -0.38 (p 0.125, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.36 (p 0.142, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.20 (p 0.418, n 18). could be the mix.
skeptic: leave-one-out range -0.46 to -0.28, sign flips 0; without severely affected donors -0.38 (p 0.125, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TNF in microglia.

case closed: nothing better to follow up.

loading the receipts